Analyst Price Target is $5.25
▲ +657.58% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Axcella Health in the last 3 months. The average price target is $5.25, with a high forecast of $8.00 and a low forecast of $2.00. The average price target represents a 657.58% upside from the last price of $0.69.
Current Consensus is
The current consensus among 4 investment analysts is to buy stock in Axcella Health. This rating has held steady since July 2022, when it changed from a Hold consensus rating.
Axcella Health, Inc. is a biotechnology company. It engages in the research and development of treatment for diseases and improves health using endogenous metabolic modulator, or EMM, and compositions. Its product pipeline includes AXA1665, for the reduction in risk of recurrent overt hepatic encephalopathy, and AXA1125, for non-alcoholic steatohepatitis. The company was founded by Noubar B. Afeyan, Geoffrey von Maltzahn, and David A. Berry on August 27, 2008 and is headquartered in Cambridge, MA.